Information Provided By:
Fly News Breaks for March 3, 2017
MDXG
Mar 3, 2017 | 06:50 EDT
Piper Jaffray analyst Matt O'Brien initiated MiMedx with an Overweight rating and $10 price target, calling it market leader for amniotic-based products that also has a large, untapped opportunity in pain management.